Immunotherapy trains the body’s own immune system to recognize and attack cancer cells while chemotherapy uses drugs that kill all rapidly dividing cells regardless of whether they’re cancerous or healthy. Immunotherapy produces longer-lasting responses in specific cancers like melanoma, lung, and kidney cancer where checkpoint inhibitors have changed survival curves dramatically. Chemotherapy remains the workhorse for most solid tumors where immune approaches haven’t yet proven superiority.

According to Dr. Sandeep Nayak, Best cancer treatment in Bangalore, “Patient walks in asking for immunotherapy because they read about it somewhere. Fair enough. But immunotherapy works brilliantly on some cancers and does absolutely nothing on others. Picking between these two isn’t a preference decision. It’s a biology decision.“

Both fight cancer. How they do it, what they damage along the way, and how long the effect lasts are where the two part company completely.

• Mechanism: Chemo poisons cell division machinery killing everything that grows fast including hair, gut lining, bone marrow alongside the tumor. Immunotherapy takes the brakes off your immune system so T-cells that were ignoring the cancer suddenly start attacking it. One is a bomb, the other is a targeted intelligence operation.
• Side effects: Chemo gives you nausea, hair loss, mouth sores, crashed blood counts. Immunotherapy causes different problems like thyroid inflammation, skin rash, colitis, hepatitis because an overactivated immune system sometimes attacks your own organs too. Neither is side-effect-free but the profiles are completely different.
• Duration of response: Chemo shrinks tumors fast but cancer bounces back in most patients once treatment stops. Immunotherapy responds slower but when it works the immune system remembers the cancer and keeps attacking long after the drug is discontinued. That memory effect is what makes immunotherapy genuinely different not just differently branded.
• Who qualifies: Chemo works on almost any cancer without needing special testing first. Immunotherapy needs PD-L1 expression testing, MSI status, or TMB analysis to predict whether the drug will help. Without these markers you’re guessing and immunotherapy guesses cost 3-4 lakhs per cycle.

Your oncologist determines which approach fits through precision oncology molecular profiling before writing a prescription.

Immunotherapy isn’t universally better. It wins specific battles spectacularly and loses others completely.

• Melanoma: Nivolumab and pembrolizumab turned advanced melanoma from a death sentence into a manageable disease for 40-50% of patients. Five-year survival rates jumped from under 10% with chemo to over 40% with checkpoint inhibitors. Possibly the single most dramatic shift in any cancer’s treatment landscape.
• Lung cancer: PD-L1 high non-small cell lung cancer responds better to pembrolizumab alone than to chemo as first-line treatment. But PD-L1 low or negative tumors still need chemo first, sometimes combined with immunotherapy. The biomarker decides the sequence not the patient’s preference or the oncologist’s habit.
• Doesn’t work well: Pancreatic cancer, most breast cancers except MSI-high or triple-negative, prostate cancer. Immune system for some reason doesn’t engage effectively against these tumors with current checkpoint inhibitors. Prescribing immunotherapy here is spending lakhs on hope rather than evidence.
• Combination approach: Many cancers now use both together. Chemo damages tumor cells releasing antigens that immunotherapy then teaches the immune system to recognize. Chemo opens the door, immunotherapy walks through it. Lung, bladder, and head and neck cancers increasingly use this combination strategy.

Knowing how chemo timing after surgery affects treatment success helps appreciate why immunotherapy sequencing follows equally strict biological logic.

Dr. Sandeep Nayak’s team at MACS Clinic runs PD-L1 testing, MSI analysis, and TMB profiling on tumor tissue before recommending immunotherapy to anyone. Medical oncologist doesn’t prescribe checkpoint inhibitors because the patient asked for them. Prescribes them because the tumor’s molecular report said they’d work.

Patient whose cancer qualifies gets immunotherapy with clear reasoning. Patient whose cancer doesn’t qualify gets told why without being made to feel like they’re getting the cheaper option. Because matching drug to biology isn’t about cost. It’s about not wasting months on something that was never going to help.

References

1. Immunotherapy in cancer treatment — National Cancer Institute
2. Checkpoint inhibitor therapy — World Health Organization

Disclaimer: The information shared in this content is for educational purposes and not for promotional use.